Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591012 | 1.00 | CASP3 (0.58) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL2591014 | 1.00 | CASP3 (0.58) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL17020410 | 0.95 | CASP3 (0.62) | CASP3KMT2AEPHX2PIN1 | |
| SCHEMBL17020411 | 0.92 | CASP3 (0.53) | CASP3KMT2AEPHX2 | |
| SCHEMBL30725734 | 0.91 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL7317762 | 0.91 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL7317767 | 0.91 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL7390390 | 0.91 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL17256589 | 0.91 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 | |
| SCHEMBL29398871 | 0.91 | CASP3 (0.52) | CASP3KMT2AEPHX2PIN1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NISSAN CHEMICAL CORPORATION (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-117343125-B | Synthesis method of antibody-coupled drug linker | 瑞博(苏州)制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117343125-A | Synthesis method of antibody-coupled drug linker | 瑞博(苏州)制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240871-B2 | Method for producing peptide compound | NGLY1, NPPA, NPEPPS | CASP3 1076/4885KMT2A 3924/4885EPHX2 4081/4885 |
| US-20220153777-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND | NGLY1, NPPA, NPEPPS | CASP3 1076/4885KMT2A 3924/4885EPHX2 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.